Compare Stocks: AMRN, CRON, AMPH, and PCRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$23.65 -0.7%	$21.19	$16.65 ▼ $29.52	$1.01B	0.92	513,400 shs	252,617 shs
AMRN Amarin	$13.62 -1.8%	$14.06	$12.96 ▼ $20.90	$286.85M	0.76	76,543 shs	32,903 shs
CRON Cronos Group	$3.36 -0.4%	$3.07	$2.28 ▼ $3.61	$1.24B	0.94	1.31 million shs	377,218 shs
PCRX Pacira BioSciences	$24.63 +0.6%	$25.39	$18.80 ▼ $27.66	$981.75M	0.26	672,477 shs	184,411 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	-0.54%	+1.19%	+11.62%	+26.63%	-11.71%
AMRN Amarin	+0.22%	-1.21%	-1.84%	-13.47%	-5.00%
CRON Cronos Group	+2.43%	+6.65%	+4.98%	+24.35%	+30.62%
PCRX Pacira BioSciences	-1.73%	-2.70%	+2.00%	+9.63%	-6.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$23.65 -0.7%	$21.19	$16.65 ▼ $29.52	$1.01B	0.92	513,400 shs	252,617 shs
AMRN Amarin	$13.62 -1.8%	$14.06	$12.96 ▼ $20.90	$286.85M	0.76	76,543 shs	32,903 shs
CRON Cronos Group	$3.36 -0.4%	$3.07	$2.28 ▼ $3.61	$1.24B	0.94	1.31 million shs	377,218 shs
PCRX Pacira BioSciences	$24.63 +0.6%	$25.39	$18.80 ▼ $27.66	$981.75M	0.26	672,477 shs	184,411 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	-0.54%	+1.19%	+11.62%	+26.63%	-11.71%
AMRN Amarin	+0.22%	-1.21%	-1.84%	-13.47%	-5.00%
CRON Cronos Group	+2.43%	+6.65%	+4.98%	+24.35%	+30.62%
PCRX Pacira BioSciences	-1.73%	-2.70%	+2.00%	+9.63%	-6.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	1.75	Reduce	$22.50	-4.82% Downside
AMRN Amarin	1.33	Sell	$13.00	-4.90% Downside
CRON Cronos Group	2.40	Hold	$2.30	-31.24% Downside
PCRX Pacira BioSciences	2.25	Hold	$29.83	21.40% Upside

Current Analyst Ratings Breakdown

Latest AMRN, CRON, AMPH, and PCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	PCRX Pacira BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
9/9/2026	CRON Cronos Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
9/9/2026	PCRX Pacira BioSciences	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$28.00
9/1/2026	PCRX Pacira BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/26/2026	CRON Cronos Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/21/2026	AMRN Amarin	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Underweight	$13.00
8/18/2026	AMPH Amphastar Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$20.00 ➝ $23.00
8/17/2026	PCRX Pacira BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
8/17/2026	AMRN Amarin	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	PCRX Pacira BioSciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$30.00
8/12/2026	CRON Cronos Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C+)

(Data available from 9/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$719.89M	1.40	$4.20 per share	5.63	$17.17 per share	1.38
AMRN Amarin	$186.23M	1.55	$0.36 per share	38.34	$22.07 per share	0.62
CRON Cronos Group	$179.09M	6.88	$0.01 per share	262.42	$3.00 per share	1.12
PCRX Pacira BioSciences	$726.41M	1.35	$3.80 per share	6.46	$16.11 per share	1.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$98.09M	$1.69	13.99	9.13	4.61	10.76%	14.98%	6.96%	11/5/2026 (Estimated)
AMRN Amarin	-$38.80M	-$0.99	N/A	N/A	N/A	-14.56%	-0.20%	-0.14%	11/4/2026 (Estimated)
CRON Cronos Group	-$9.45M	$0.20	16.73	N/A	N/A	39.08%	4.85%	4.62%	11/5/2026 (Estimated)
PCRX Pacira BioSciences	$7.03M	$0.35	70.27	10.24	N/A	1.96%	9.68%	5.30%	11/5/2026 (Estimated)

Latest AMRN, CRON, AMPH, and PCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AMPH Amphastar Pharmaceuticals	$0.62	$0.91	+$0.29	$0.67	$179.92 million	$183.90 million
8/6/2026	Q2 2026	CRON Cronos Group	$0.01	$0.09	+$0.08	$0.09	$44.20 million	$53.01 million
8/4/2026	Q2 2026	PCRX Pacira BioSciences	$0.6460	$0.73	+$0.0840	$0.12	$191.06 million	$192.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
PCRX Pacira BioSciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.79	2.40	1.71
AMRN Amarin	N/A	3.67	2.67
CRON Cronos Group	N/A	16.18	15.25
PCRX Pacira BioSciences	0.54	5.04	3.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
AMRN Amarin	22.25%
CRON Cronos Group	8.71%
PCRX Pacira BioSciences	99.73%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	29.60%
AMRN Amarin	4.21%
CRON Cronos Group	7.80%
PCRX Pacira BioSciences	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,976	42.54 million	29.95 million	Optionable
AMRN Amarin	80	21.12 million	20.23 million	Optionable
CRON Cronos Group	610	368.54 million	339.80 million	Optionable
PCRX Pacira BioSciences	829	39.86 million	37.31 million	Optionable

AMRN, CRON, AMPH, and PCRX Headlines

Recent News About These Companies

Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $29.83

September 16 at 3:45 AM | americanbankingnews.com

Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Hold" from Brokerages

September 11, 2026 | marketbeat.com

Leerink Partners Initiates Coverage on Pacira BioSciences (NASDAQ:PCRX)

September 11, 2026 | americanbankingnews.com

Leerink Partners initiates coverage of Pacira BioSciences at market perform

September 10, 2026 | msn.com

Pacira BioSciences (NASDAQ:PCRX) Now Covered by Leerink Partners

September 9, 2026 | marketbeat.com

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 9, 2026 | globenewswire.com

Public Employees Retirement System of Ohio Purchases New Position in Pacira BioSciences, Inc. $PCRX

September 9, 2026 | marketbeat.com

Wellington Management Group LLP Has $14.29 Million Holdings in Pacira BioSciences, Inc. $PCRX

September 8, 2026 | marketbeat.com

Legal & General Group Plc Buys Shares of 88,640 Pacira BioSciences, Inc. $PCRX

September 6, 2026 | marketbeat.com

296,880 Shares in Pacira BioSciences, Inc. $PCRX Purchased by Bank of New York Mellon Corp

September 4, 2026 | marketbeat.com

Man Group plc Buys New Holdings in Pacira BioSciences, Inc. $PCRX

September 1, 2026 | marketbeat.com

200,073 Shares in Pacira BioSciences, Inc. $PCRX Acquired by Empowered Funds LLC

September 1, 2026 | marketbeat.com

PDT Partners LLC Makes New Investment in Pacira BioSciences, Inc. $PCRX

August 27, 2026 | marketbeat.com

Foster & Motley Inc. Buys New Holdings in Pacira BioSciences, Inc. $PCRX

August 20, 2026 | marketbeat.com

Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares

August 19, 2026 | insidertrades.com

Rice Hall James & Associates LLC Purchases Shares of 93,396 Pacira BioSciences, Inc. $PCRX

August 19, 2026 | marketbeat.com

Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy?

August 10, 2026 | finance.yahoo.com

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform

August 8, 2026 | seekingalpha.com

Pacira BioSciences (PCRX) Could Be 35% Undervalued On Phase 1 Gene Therapy Progress

August 6, 2026 | finance.yahoo.com

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in ...

August 6, 2026 | caledonianrecord.comC

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

August 6, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AMRN, CRON, AMPH, and PCRX Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$23.80 -0.02 (-0.09%)

As of 03:53 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Amarin NASDAQ:AMRN

$13.61 -0.26 (-1.90%)

As of 03:53 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Cronos Group NASDAQ:CRON

$3.34 -0.02 (-0.74%)

As of 03:53 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Pacira BioSciences NASDAQ:PCRX

$24.57 +0.09 (+0.38%)

As of 03:53 PM Eastern

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMRN, CRON, AMPH, and PCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMRN, CRON, AMPH, and PCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMRN, CRON, AMPH, and PCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AMRN, CRON, AMPH, and PCRX Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

Amarin NASDAQ:AMRN

Cronos Group NASDAQ:CRON

Pacira BioSciences NASDAQ:PCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMRN, CRON, AMPH, and PCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMRN, CRON, AMPH, and PCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMRN, CRON, AMPH, and PCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AMRN, CRON, AMPH, and PCRX Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

Amarin NASDAQ:AMRN

Cronos Group NASDAQ:CRON

Pacira BioSciences NASDAQ:PCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools